The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis.
The press release from Otsuka can be found here
TB Drug Fighting Resistant Strains Wins Europe Approval
Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults